The Patient-Reported Outcomes, Survey, and Population Research (PROSPR) shared resource is a centralized source of expertise in the science of collecting and managing participant-reported outcome (PRO) and behavioral data. These data are important in many treatment trials (e.g., to evaluate the impact of treatment on quality of life and symptoms), survivorship studies, and in cancer prevention research. The PROSPR offers services in 3 areas: research support services, which have seen a 100% increase in utilization over the past 5 years, data support services (12% increase), and fitness and body composition testing (new service in 2011). PROSPR has access to a SQL server, as well as equipment for testing fitness and body composition (Hologic bone densitometer, Biodex for measuring strength, 3 metabolic carts, 3 ECGs, 2 cycle ergometers, 1 treadmill, a perometer, and a bank of 150 actigraphs). In the past 5 years, the PROSPR facility has served 112 investigators in 17 programs. PROSPR has facilitated 47 publications with articles appearing in JAMA and J Clin Oncol. Center members with peer-reviewed funding account for 80% of users, and 32% of total costs are requested from the CCSG. The institution has provided $431,072 in financial support for the shared resource since 2008 for operational costs and for equipment, including an HP server, 3 Dell precision workstations, and 150GT3XE-plus triaxial activity monitors. In addition, the fitness and body composition equipment was purchased by the institution. Over the next 5 years, PROSPR will improve its expertise and expand services in design and data management for computer-assisted data collection (e.g., ecological momentary assessment, computer adaptive testing, and internet-based surveys) and expand its expertise in body composition testing.

Public Health Relevance

PROSPR provides assistance to MD Anderson investigators with collection and assessment of Patient Reported Outcomes, behavioral data, and measures of fitness and body composition. These data are central to cancer prevention and survivorship research, and are increasingly incorporated being into cancer treatment trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016672-38
Application #
8557380
Study Section
Subcommittee G - Education (NCI)
Project Start
1998-09-04
Project End
2018-06-30
Budget Start
2013-09-06
Budget End
2014-06-30
Support Year
38
Fiscal Year
2013
Total Cost
$256,492
Indirect Cost
$96,216
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Chang, Geraldine H; Kurzrock, Razelle; Tran, Lisa et al. (2018) TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [18F] fluorodeoxyglucose (18F-FDG PET). Oncotarget 9:14306-14310
Abaza, Yasmin; Cortes, Jorge; Ravandi, Farhad et al. (2018) Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. Am J Hematol 93:E357-E360
Ellrott, Kyle; Bailey, Matthew H; Saksena, Gordon et al. (2018) Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst 6:271-281.e7
White, Matthew C; Schroeder, Rebecca D; Zhu, Keyi et al. (2018) HRI-mediated translational repression reduces proteotoxicity and sensitivity to bortezomib in human pancreatic cancer cells. Oncogene 37:4413-4427
Abaza, Yasmin; Hidalgo-Lopez, Juliana E; Verstovsek, Srdan et al. (2018) Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leuk Res 73:78-85
McGrail, Daniel J; Federico, Lorenzo; Li, Yongsheng et al. (2018) Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. Nat Commun 9:1317
Li, Carrie J; Jiang, Changying; Liu, Yang et al. (2018) Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma. Mol Cancer Ther :
Morita, Kiyomi; Kantarjian, Hagop M; Wang, Feng et al. (2018) Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol 36:1788-1797
Raber, Benjamin; Bea, Vivian J; Bedrosian, Isabelle (2018) How Does MR Imaging Help Care for My Breast Cancer Patient? Perspective of a Surgical Oncologist. Magn Reson Imaging Clin N Am 26:281-288
Li, Roger; Metcalfe, Michael J; Ferguson 3rd, James E et al. (2018) Effects of thiazolidinedione in patients with active bladder cancer. BJU Int 121:244-251

Showing the most recent 10 out of 12418 publications